Biocardia Stock Today

BCDA -  USA Stock  

USD 2.20  0.03  1.35%

Biocardia is trading at 2.20 as of the 28th of November 2021, a -1.35% down since the beginning of the trading day. The stock's open price was 2.23. Biocardia has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Biocardia are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2019 and ending today, the 28th of November 2021. Please note, there could be an existing legal relationship between Biocardia (BCDA) and BioCardia (CKST). Click here to learn more.
Market Performance
0 of 100
Odds Of Distress
Less than 2
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine and Morph deflectable guides and sheaths. The company has 16.79 M outstanding shares of which 196.97 K shares are currently shorted by private and institutional investors with about 4.47 trading days to cover. More on Biocardia

Biocardia Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Biocardia's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Biocardia or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Biocardia generated a negative expected return over the last 90 days
Biocardia has high historical volatility and very poor performance
Biocardia is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 195 K. Net Loss for the year was (13.29 M) with loss before overhead, payroll, taxes, and interest of (9.67 M).
Biocardia currently holds about 18.54 M in cash with (11.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.1.
Biocardia has a poor financial position based on the latest SEC disclosures
Roughly 31.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Purchase by Peter Altman of 5000 shares of Biocardia
Biocardia Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Biocardia SEC Filings
Biocardia SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameBiocardia
Related EntityCKST (BioCardia)
CEOPeter Altman  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Biocardia report their recommendations after researching Biocardia's financial statements, talking to executives and customers, or listening in on Biocardia's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Biocardia. The Biocardia consensus assessment is calculated by taking the average forecast from all of the analysts covering Biocardia.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Biocardia based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Biocardia financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares10.9 M10.1 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted10.9 M10.1 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations(12.7 M)(12.4 M)
Fairly Down
Decreasing
Slightly volatile
Total Assets19.6 M23.4 M
Fairly Down
Increasing
Slightly volatile
Total Liabilities3.7 M4.2 M
Fairly Down
Increasing
Slightly volatile
Current Assets18.8 M22.7 M
Significantly Down
Increasing
Slightly volatile
Current Liabilities3.6 M4.2 M
Fairly Down
Increasing
Slightly volatile
Total Debt630.2 K614 K
Fairly Up
Decreasing
Slightly volatile
Return on Average Assets(1.22)(1.19)
Fairly Down
Decreasing
Slightly volatile
Gross Margin1.050.972
Significantly Up
Decreasing
Stable
Asset Turnover0.01130.011
Fairly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Biocardia's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Biocardia's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Biocardia's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biocardia's financial leverage. It provides some insight into what part of Biocardia's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Biocardia's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Biocardia deploys its capital and how much of that capital is borrowed.
Liquidity
Biocardia cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 316 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Biocardia has a current ratio of 4.25, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(12.68 Million)Share
Biocardia (BCDA) is traded on NASDAQ Exchange in USA. It is located in 125 Shoreway Road and employs 24 people. Biocardia is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 36.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biocardia's market, we take the total number of its shares issued and multiply it by Biocardia's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Biocardia conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 16.79 M outstanding shares of which 196.97 K shares are currently shorted by private and institutional investors with about 4.47 trading days to cover. Biocardia currently holds about 18.54 M in cash with (11.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.1.
Check Biocardia Probability Of Bankruptcy
Ownership
Biocardia retains a total of 16.79 Million outstanding shares. Biocardia retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Biocardia Ownership Details

Biocardia Stock Price Odds Analysis

What are Biocardia's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Biocardia jumping above the current price in 90 days from now is about 98.0%. The Biocardia probability density function shows the probability of Biocardia stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Biocardia has a beta of 0.9082 suggesting Biocardia market returns are sensitive to returns on the market. As the market goes up or down, Biocardia is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Biocardia is significantly underperforming DOW.
 Odds Down 2.2HorizonTargetOdds Up 2.2 
1.94%90 days
 2.20 
98.04%
Based on a normal probability distribution, the odds of Biocardia to move above the current price in 90 days from now is about 98.0 (This Biocardia probability density function shows the probability of Biocardia Stock to fall within a particular range of prices over 90 days) .

Biocardia Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Biocardia that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Biocardia's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Biocardia's value.
InstituionSecurity TypeTotal SharesValue
Roumell Asset Management LlcCommon Shares938.4 K2.9 M
Captrust Financial AdvisorsCommon Shares660.6 K2.1 M
Captrust Financial AdvisorsWarrants500 K812 K
Susquehanna International Group LlpCall Options33.5 K105 K
Simplex Trading LlcPut Options14.3 K55 K
View Biocardia Diagnostics

Biocardia Historical Income Statement

Biocardia Income Statement is one of the three primary financial statements used for reporting Biocardia's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Biocardia revenue and expense. Biocardia Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Biocardia Cost of Revenue is projected to decrease significantly based on the last few years of reporting. The past year's Cost of Revenue was at 4,000. The current year Interest Expense is expected to grow to 3,079, whereas Consolidated Income is forecasted to decline to (15.4 M). View More Fundamentals

Biocardia Stock Against Markets

Picking the right benchmark for Biocardia stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Biocardia stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Biocardia is critical whether you are bullish or bearish towards Biocardia at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Biocardia without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pair Correlation Now

   

Pair Correlation

Compare performance and examine fundamental relationship between any two equity instruments
All  Next Launch Module

Biocardia Corporate Directors

Biocardia corporate directors refer to members of a Biocardia board of directors. The board of directors generally takes responsibility for the Biocardia's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Biocardia's board members must vote for the resolution. The Biocardia board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Continue to Trending Equities. Note that the Biocardia information on this page should be used as a complementary analysis to other Biocardia's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Biocardia Stock analysis

When running Biocardia price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Is Biocardia's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine Biocardia value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.